Nonalcoholic fatty liver disease

INSTRUCTIONS Nonalcoholic fatty liver disease: What nurses need to know TEST INSTRUCTIONS Read the article. The test for this CE activity is to be taken online at www. nursingcenter. com/CE/nursing. You'll need to create (it's free!) and log in to your personal CE Planner account before taking online tests. Your planner will keep track of all your Lippincott Professional Development online CE activities for you. There's only one correct answer for each question. A passing score for this test is 14 correct answers. If you pass, you can print your certificate of earned contact hours and access the answer key. If you fail, you have the option of taking the test again at no additional cost. For questions, contact Lippincott Professional Development: 1-800-787-8985. Registration deadline is March 4, 2022. PROVIDER ACCREDITATION Lippincott Professional Development will award 1. 5 contact hours and 0. 5 pharmacology credits for this continuing nursing education activity. Lippincott Professional Development is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center's Commission on Accreditation. This activity is also provider approved by the California Board of Registered Nursing, Provider Number CEP 11749 for 1. 5 contact hours, and the District of Columbia, Georgia, and Florida CE Broker #50-1223. Payment: The registration fee for this test is 17. 95. Nonalcoholic fatty liver disease: What nurses need to know GENERAL PURPOSE: To provide an overview of NAFLD. LEARNING OBJECTIVES/OUTCOMES: After completing this continuing-education activity, you should be able to: 1. Describe risk factors for NAFLD. 2. List the clinical manifestations of NAFLD. 3. Outline nursing interventions for patients with NAFLD. What distinguishes NASH from NAFLD? elevated liver enzymes significant hepatic inflammation excess hepatic fat Which is a diagnostic criterion for metabolic syndrome? FPG of 100 mg/dL or more serum triglycerides less than 150 mg/dL without drug therapy waist circumference of 88 cm or more in men The loss of hepatocytes associated with the aging process leads to reductions in serum levels of alkaline phosphatase. aminotransferase. albumin. Along with cardiovascular disease, which is a common cause of death in patients with NAFLD and NASH? malignancies diabetes mellitus pneumococcal disease Which of the following is an independent predictor of advanced liver fibrosis in patients with NAFLD? OSA IR POS A medication known to trigger NAFLD is ezetimibe. pioglitazone. amiodarone. Individuals of which ethnicity are more susceptible to NAFLD? Asian Hispanic African American What is the most common initial manifestation of NAFLD? fatigue jaundice abdominal pain The preferred initial radiologic study to assess for fatty infiltration of the liver is computed tomography. MRE. transabdominal liver ultrasound. What is used to assess the extent of liver stiffness? liver fibrosis panel TE liver biopsy The NAS assigns a score of 0 to 2 to steatosis. lobular inflammation. hepatocellular ballooning. Fibrosis spreading and forming bridges with other fibrotic liver areas is staged as F2. F3. F4. To resolve mild-to-moderate fibrosis, the AASLD recommends that patients reduce body weight by 5%. 10%. 15%. Nutritional recommendations for patients with NAFLD include having 40% to 50% of total dietary intake comprised of low-fiber foods. carbohydrates. lean proteins. Fatty liver is caused by an accumulation of low-density lipoprotein cholesterol. HDL cholesterol. triglycerides. Which cholesterol-lowering medication has been shown to significantly improve visceral fat areas and levels of fasting insulin, triglycerides, and cholesterol? ezetimibe gemfibrozil rosuvastatin Which of the following supplements does the AASLD recommend considering for adults without diabetes who have biopsy-proven NASH? vitamin A vitamin D vitamin E A diet rich in which of the following has been proven beneficial for patients with NAFLD and NASH? low-fat dairy products whole grains lean protein Up to what percentage of patients with NAFLD will progress to NASH? 5% 10% 20%